-
2024-519655-28-00
5
2026-04-23
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2023-507485-10-00
9
2026-04-21
advanced breast cancer
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2025-521327-67-00
4
2026-04-13
Metastatic Castration-Resistant Prostate Cancer
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2024-519578-38-00
10
2026-03-30
Classic congenital adrenal hyperplasia
-
2025-521142-22-00
5
2026-03-27
Hereditary Angioedema
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2024-519537-29-00
1
2026-03-13
Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2022-501607-27-00
7
2026-01-06
Relapsed or refractory B-cell Non-Hodgkin lymphoma
-
2024-511508-18-00
9
2026-01-05
Chronic graft versus host disease.
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-521672-60-00
7
2025-12-19
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re